Tags Archive Navigation
icon
-
Media ReleaseNovartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
-
Media ReleaseNovartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
-
Media ReleaseNovartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis
-
Media ReleaseNovartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Media ReleaseNovartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
-
Media ReleaseNovartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis
-
Media ReleaseNovartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
-
Media ReleaseNovartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience
-
Media ReleaseNovartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media ReleaseSandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
-
Media ReleaseNovartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis